Company: ABUS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001447028-25-000083
Chunk: 5

Company: Arbutus Biopharma Corp
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 5
---
,251)(3,867)Non-cash interest expense127 455 Net accretion and amortization of investments in marketable securities(3,135)(2,196)Net change in operating items:Accounts receivable(633)(424)Prepaid expenses and other assets2,298 (943)Accounts payable and accrued liabilities(2,707)(5,758)Change in deferred license revenue(1,357)(10,664)Other liabilities(430)(444)Net cash used in operating activities(64,850)(85,936)INVESTING ACTIVITIES  Purchase of investments in marketable securities(141,509)(80,509)Disposition of investments in marketable securities164,639 132,270 Proceeds from sale of property and equipment— 20 Acquisition of property and equipment(182)(1,008)Net cash provided by investing activities22,948 50,773 FINANCING ACTIVITIES  Issuance of common shares pursuant to the Open Market Sale Agreement44,123 29,852 Issuance of common shares pursuant to exercise of stock options7,477 260 Issuance of common shares pursuant to exercise of ESPP396 535 Net cash provided by financing activities51,996 30,647 Effect of foreign exchange rate changes on cash and cash equivalents(49)25 Increase / (decrease) in cash and cash equivalents$10,045 $(4,491)Cash and cash equivalents, beginning of period$26,285 $30,776 Cash and cash equivalents, end of period$36,330 $26,285 

See accompanying notes to the consolidated financial statements.

 80